India's Orchid Pharma up on getting drug combination approval

Orchid Pharma

06/06/2024 10:01

** Shares of Orchid Pharma  ORCD.NS  up 8.1% at 1,080 rupees
after rising up as much as 9.2%
    ** Co said it has received DCGI approval for its antibiotic
drug combination of Cefepime and Enmetazobactam
    ** Adds, approval paves the way for launch of the advanced
injectable therapy for patients in India
    ** Formulation is indicated for the treatment of complicated
urinary tract infections - ORCD
    ** Avg rating of three analysts equivalent of "strong buy",
median PT is 1,247 rupees - LSEG data
    ** Stock rose 46.7% in March quarter, its highest quarterly
rise since March 2021
    ** Stock up 51.6% YTD



 (Reporting by Ashish Chandra in Bengaluru)
 ((ashish.chandra@thomsonreuters.com (+91 7982114624))